Pitt | Swanson Engineering
Development of a Compliance Matched Biopolymer Tissue Engineered Vascular Graft (TEVG)
  • Development of a Compliance Matched Biopolymer Tissue Engineered Vascular Graft (TEVG)


Stenotic vascular disease represents a significant health concern in the United States and around the world.  Current bypass procedures in both the coronary and peripheral vasculature where small diameter vascular substitutes are required suffer from graft thrombosis and/or restenosis. The STBL and collaborators are developing a small diameter compliance matched tissue engineered vascular graft (TEVG) for use as a small diameter vascular substitute. Novel native biopolymers are being synthesized using state of the art techniques in biomanufacturing using a computationally optimized approach. Significant efforts are also being made to improve the antithrombogenicity and vasoactivity of our TEVG. Preclinical in-vivo assessment of our graft has been initiated as well as in-vitro assessment of our TEVGs remodeling dynamics using a physiological in-vito bioreactor in combination with an intravital microscope. This project is a multi-disciplinary effort spanning several basic science disciplines across multiple universities (see below list of collaborators). 


tevgbioreactor1tevgbioreactor2tevg1



Collaborators on this project include:

  • William Wagner (University of Pittsburgh)
  • Thomas Gleason (University of Pittsburgh)
  • Kang Kim (University of Pittsburgh)
  • Thomas Doetschman (University of Arizona)
  • David Harris (University of Arizona)
  • Oliver McIntyre (Vanderbilt University)
  • Rob Kellar (N. Arizona University)
  • Burt Ensley (Protein Genomics)